Où consulte Pr Emmanuelle Dernis ?

Pr Emmanuelle Dernis consulte à CHU CAEN, Avenue COTE DE NACRE, 14033 Caen. Adresses issues de l'Annuaire Santé (ANS).

Comment prendre rendez-vous avec Pr Emmanuelle Dernis ?

Par téléphone au 02 31 06 31 06 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.

D'où viennent les informations de cette page ?

Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.

Pr Emmanuelle DernisRhumatologue à Caen

Hospitalo-universitaire

Appeler· 02 31 06 31 06 Rechercher sur Doctolib

Spondyloarthrite Traitements locaux, non médicamenteux et kinésithérapie 8'22Dr Emmanuelle Dernismohamed mammeri
Emmanuelle DERNIS Le rhumatisme psoriasiqueCOFER

Photo : Viault, CC BY-SA 3.0, Wikimedia Commons

Dans les médias

Ouest-France
COFER
mohamed mammeri

Vous êtes Pr Emmanuelle Dernis ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.

Configurer votre fiche gratuitement →

Pr Emmanuelle Dernis est rhumatologue à Caen (14033). Il consulte à CHU CAEN, Avenue COTE DE NACRE, 14033 Caen.

Enregistrer le contact

publications: 50publications
citations: 3 555citations
vidéos: 2vidéos
article de presse: 1article de presse

Consulter

Lieu de consultation

CHU CAEN
Avenue COTE DE NACRE, 14033 Caen

Pr Emmanuelle Dernis, c'est vous ?

Faites de cette fiche la page de votre cabinet.

Votre présentationQuelques lignes sur votre pratique, affichées en tête de page.
Vos domaines d'expertiseLes pathologies que vous suivez, à la place des domaines déduits.
Vos actesÉchographie, infiltrations, viscosupplémentation, PRP, téléexpertise.
Vos liensSite du cabinet, LinkedIn, secteur de conventionnement corrigé.

Configurer votre fiche gratuitementGratuit · réservé au praticien

Polyarthrite rhumatoïde · 11

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2026RMD openPubMed

Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study

2026RMD openPubMed

Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort

2026Joint bone spinePubMed

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

2026Rheumatology and therapyPubMed

Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study

2025The Lancet. RheumatologyPubMed

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

2025Rheumatology (Oxford, England)PubMed

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

2025RMD openPubMed

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study

2024Joint bone spinePubMed

2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis

2024Arthritis & rheumatology (Hoboken, N.J.)PubMed

Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission

2022Joint bone spinePubMed

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

Spondyloarthrite · 11

2026RMD openPubMed

Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort

2026Rheumatology (Oxford, England)PubMed

Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care

2026Annals of the rheumatic diseasesPubMed

Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study

2025RMD openPubMed

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

Rhumatisme psoriasique · 10

2025Rheumatology (Oxford, England)PubMed

Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study

2025The Journal of rheumatologyPubMed

Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic Arthritis

2025Rheumatology (Oxford, England)PubMed

How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients

2024Rheumatology (Oxford, England)PubMed

An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis

Polymyalgia rheumatica · 6

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2025The Lancet. RheumatologyPubMed

Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial

2024Joint bone spinePubMed

Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica

2024RMD openPubMed

Concordance and agreement between different activity scores in polymyalgia rheumatica

Biothérapies non-anti-TNF · 5

2025Rheumatology (Oxford, England)PubMed

Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2024Arthritis & rheumatology (Hoboken, N.J.)PubMed

2023The Lancet. RheumatologyPubMed

Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial

JAK inhibiteurs · 5

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2026Joint bone spinePubMed

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

2025The Lancet. RheumatologyPubMed

Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial

2025RMD openPubMed

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study

Transversal · 5

2026Diagnosis (Berlin, Germany)PubMed

Development of a simple diagnostic tool predicting the aseptic nature of a joint effusion: a pragmatic pilot study

2023Joint bone spinePubMed

Comparing COVID-19 disease severity in patients with rheumatic and inflammatory diseases between the first and the subsequent waves

2022Annals of the rheumatic diseasesPubMed

Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017

2022Clinical and experimental rheumatologyPubMed

Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study

csDMARDs · 4

2026Rheumatology and therapyPubMed

Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study

2025The Lancet. RheumatologyPubMed

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

2022Revue du rhumatisme (Ed. francaise : 1993)PubMed

Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2 : étude de 871 patients

2021Joint bone spinePubMed

Sjögren · 4

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data

2025RMD openPubMed

Impact of Sjögren's disease on quality of sexual life using the Qualisex score

2024The Lancet. RheumatologyPubMed

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

2024RMD openPubMed

Characterisation of airway disease associated with Sjögren disease

Anti-TNF · 2

2025Rheumatology (Oxford, England)PubMed

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

2022Joint bone spinePubMed

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

Anti-IL-17 · 1

2022Rheumatology (Oxford, England)PubMed

New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study

IA en rhumatologie · 1

2025RMD openPubMed

When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

Myopathies inflammatoires · 1

2023RMD openPubMed

In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study

Risque cardio-vasculaire · 1

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

Pr Emmanuelle DernisRhumatologue à Caen

Lieu de consultation

Préparer votre rendez-vous

Conventionnement et remboursement

Expertise et points clés

Parcours et diplômes (9)

Travaux scientifiques (58)

Vidéos et presse (3)

Questions fréquentes sur Pr Emmanuelle Dernis

Où consulte Pr Emmanuelle Dernis ?

Comment prendre rendez-vous avec Pr Emmanuelle Dernis ?

D'où viennent les informations de cette page ?

Rhumatologues à Caen et alentours